BioMarin Pharmaceutical reported a significant top-line expansion in the second quarter of 2026, driven by the successful closing of the Amicus Therapeutics acquisition and sustained demand for its growth therapies. Total revenues grew 20% year-over-year to $990 million, while non-GAAP diluted EPS of $1.20 substantially exceeded analyst estimates. The company leveraged this momentum to raise its full-year 2026 guidance for revenue, Voxzogo sales, and non-GAAP earnings.
Key Highlights
- Total revenues reached $990 million, up 20% year-over-year, primarily driven by the inclusion of Galafold and Pombiliti + Opfolda following the April 27, 2026, close of the Amicus acquisition.
- Management raised full-year 2026 revenue guidance to a range of $3.88 billion to $3.93 billion and increased full-year non-GAAP diluted EPS guidance to $4.90–$5.10.
- Voxzogo revenue increased 14% to $253 million, prompting the company to raise its full-year guidance for the drug to at least $1 billion in 2026.
- The company identified approximately $220 million in non-GAAP cost synergies from the Amicus integration expected by 2028 and accelerated its deleveraging timeline, targeting gross leverage below 2.5x by mid-2027.